Literature DB >> 1498321

Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP).

Y Furukawa1, J Fujisawa, M Osame, M Toita, S Sonoda, R Kubota, S Ijichi, M Yoshida.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) integrates its proviruses into random sites in host chromosomal DNA. Random integration of the proviruses was observed in asymptomatic HTLV-1 carriers and patients with HTLV-1-associated myelopathy (HAM/TSP). However, clonal integration has been reported in patients with adult T-cell leukemia (ATL), including that in the smoldering, chronic, and acute states, indicating clonal expansion of infected cells. In this study, we found that about 20% of HAM/TSP patients and their seropositive family members harbored subpopulation(s) of clonally proliferated cells infected with HTLV-1, although they still maintained randomly infected cells as a major population. These clones were stable during examination periods of 4 months to 3 years. However, these carriers or HAM/TSP patients did not show any significant indication of ATL. This extremely high frequency of clonal expansion of HTLV-1-infected cells indicates that some clones of HTLV-1-infected cells have a tendency to proliferate more efficiently than the other population without malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1498321

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

2.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

3.  Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus).

Authors:  F Mortreux; M Kazanji; A S Gabet; B de Thoisy; E Wattel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax.

Authors:  Y Koya; T Ohashi; H Kato; S Hanabuchi; T Tsukahara; F Takemura; K Etoh; M Matsuoka; M Fujii; M Kannagi
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 5.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

6.  Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.

Authors:  E Wattel; J P Vartanian; C Pannetier; S Wain-Hobson
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

8.  High human T cell leukemia virus type-1(HTLV-1) provirus load in patients with HTLV-1 carriers complicated with HTLV-1-unrelated disorders.

Authors:  Daisuke Sasaki; Yuko Doi; Hiroo Hasegawa; Katsunori Yanagihara; Kunihiro Tsukasaki; Masako Iwanaga; Yasuaki Yamada; Toshiki Watanabe; Shimeru Kamihira
Journal:  Virol J       Date:  2010-04-28       Impact factor: 4.099

9.  High incidence of HAM/TSP-like symptoms in WKA rats after administration of human T-cell leukemia virus type 1-producing cells.

Authors:  S Kushida; H Mizusawa; M Matsumura; H Tanaka; Y Ami; M Hori; K Yagami; T Kameyama; Y Tanaka; A Yoshida
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Clinical Trials and Treatment of ATL.

Authors:  Kunihiro Tsukasaki; Kensei Tobinai
Journal:  Leuk Res Treatment       Date:  2012-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.